ATE212230T1 - Methoden zur krankheitsbehandlung unter verwendung von sertoli-zellen und allotransplantat oder xenotransplantat - Google Patents

Methoden zur krankheitsbehandlung unter verwendung von sertoli-zellen und allotransplantat oder xenotransplantat

Info

Publication number
ATE212230T1
ATE212230T1 AT95916368T AT95916368T ATE212230T1 AT E212230 T1 ATE212230 T1 AT E212230T1 AT 95916368 T AT95916368 T AT 95916368T AT 95916368 T AT95916368 T AT 95916368T AT E212230 T1 ATE212230 T1 AT E212230T1
Authority
AT
Austria
Prior art keywords
cells
sertoli cells
allotransplant
xenotransplant
methods
Prior art date
Application number
AT95916368T
Other languages
English (en)
Inventor
Helena P Selawry
Original Assignee
Res Corp Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Corp Technologies Inc filed Critical Res Corp Technologies Inc
Application granted granted Critical
Publication of ATE212230T1 publication Critical patent/ATE212230T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0683—Cells of the male genital tract, e.g. prostate, epididymis; Non-germinal cells from testis, e.g. Leydig cells, Sertoli cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C12N5/0677—Three-dimensional culture, tissue culture or organ culture; Encapsulated cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/24—Genital tract cells, non-germinal cells from gonads
    • C12N2502/246—Cells of the male genital tract, non-germinal testis cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT95916368T 1994-04-13 1995-04-13 Methoden zur krankheitsbehandlung unter verwendung von sertoli-zellen und allotransplantat oder xenotransplantat ATE212230T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21169594A 1994-04-13 1994-04-13
PCT/US1995/004565 WO1995028167A1 (en) 1994-04-13 1995-04-13 Methods of treating disease using sertoli cells and allografts or xenografts

Publications (1)

Publication Number Publication Date
ATE212230T1 true ATE212230T1 (de) 2002-02-15

Family

ID=22787974

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95916368T ATE212230T1 (de) 1994-04-13 1995-04-13 Methoden zur krankheitsbehandlung unter verwendung von sertoli-zellen und allotransplantat oder xenotransplantat

Country Status (12)

Country Link
US (3) US5725854A (de)
EP (1) EP0755258B1 (de)
JP (1) JPH09512015A (de)
AT (1) ATE212230T1 (de)
AU (1) AU715177B2 (de)
CA (1) CA2187803C (de)
DE (1) DE69525151T2 (de)
DK (1) DK0755258T3 (de)
ES (1) ES2169128T3 (de)
FI (2) FI120670B (de)
NO (1) NO320713B1 (de)
WO (1) WO1995028167A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA961018B (en) * 1995-02-08 1997-08-08 Yamanouchi Europ Bv Oral dosage-forms containing a beta-lactam antibiotic.
EP0814819B1 (de) * 1995-03-13 2004-07-14 University Of South Florida Sertolizellen als transplantationunterstützer bei zelltransplantationen
US5830460A (en) 1995-03-13 1998-11-03 University Of South Florida Sertoli cells as transplantation facilitator for cell transplantation
US5702700A (en) * 1995-03-13 1997-12-30 University Of South Florida Sertoli cells as neurorecovery inducing cells for Parkinson's disease
AU5390696A (en) * 1995-04-20 1996-11-07 University Of South Florida Purified and isolated sertoli cell aggregate
US6037175A (en) * 1996-03-12 2000-03-14 The University Of South Florida Method and media for enhancing cryopreservation of cells
JP2002500202A (ja) * 1998-01-02 2002-01-08 タイタン ファーマシューティカルズ, インコーポレイテッド 免疫優位部位の生成のための色素性網膜上皮細胞の使用
US7399751B2 (en) * 1999-11-04 2008-07-15 Sertoli Technologies, Inc. Production of a biological factor and creation of an immunologically privileged environment using genetically altered Sertoli cells
WO2000027409A1 (en) * 1998-11-06 2000-05-18 Kirkpatrick Shaun A Production of a biological factor and creation of an immunologically privileged environment using genetically altered sertoli cells
PL191994B1 (pl) 1998-12-15 2006-08-31 Univ Mexico Nacional Autonoma Sposób i urządzenie do wspomagania implantowania materiału biologicznego
US6365385B1 (en) 1999-03-22 2002-04-02 Duke University Methods of culturing and encapsulating pancreatic islet cells
US6303355B1 (en) 1999-03-22 2001-10-16 Duke University Method of culturing, cryopreserving and encapsulating pancreatic islet cells
US7115256B1 (en) * 1999-04-09 2006-10-03 Titan Pharmaceuticals, Inc. Methods of treating schizophrenia
DK1248640T3 (da) 2000-01-20 2007-02-12 Diabcell Pty Ltd Xenotransplantation af svineöer og deres fremstilling
US6790441B1 (en) 2000-06-13 2004-09-14 University Of South Florida Sertoli cells as biochambers
AU9118201A (en) 2000-09-20 2002-04-02 Islet Sheet Medical Llc Improved methods for fabrication of thin sheet bio-artificial organs
CN1289063C (zh) 2001-05-11 2006-12-13 奥索-麦克尼尔药品公司 用于动物的免疫调节装置
ATE535601T1 (de) * 2001-09-28 2011-12-15 Diabcell Pty Ltd Züchtung von fremdtransplantationsmaterial in kultur
WO2003070275A1 (en) * 2002-02-22 2003-08-28 Prophy Med Ab Use of an inhibitor or antagonist against tissue factor
US20040062753A1 (en) * 2002-09-27 2004-04-01 Alireza Rezania Composite scaffolds seeded with mammalian cells
EP1636346A4 (de) * 2003-06-24 2007-03-28 Diabcell Pty Ltd Mit sertolizellen aus schwein kultivierte inselzellen aus schwein zur xenotransplantation
EP1648380B1 (de) * 2003-07-03 2015-04-08 Sertoli Technologies, LLC Zusammensetzungen mit sertoli-zellen und myoid-zellen und ihre verwendung in zellulären transplanten
WO2006118564A2 (en) * 2004-04-29 2006-11-09 Washington State University Research Foundation MODIFIED CELLS EXPRESSING A PROTEIN THAT MODULATES ACTIVITY OF bHLH PROTEINS, AND USES THEREOF
NZ553080A (en) 2004-07-29 2010-10-29 Univ Miami A device for receiving implanted biological material
US20070065422A1 (en) * 2005-09-20 2007-03-22 Cameron Don F Induction of immune tolerance by sertoli cells
US20090028833A1 (en) * 2006-01-26 2009-01-29 John Constance M Proliferative Primary Human Sertoli Cell Cultures And Their Applications
JP2010500871A (ja) * 2006-07-28 2010-01-14 セルトセル・バイオテクノロジー・(ユーエス)・コーポレイション 成熟セルトリ細胞およびその使用
WO2009105278A2 (en) 2008-02-21 2009-08-27 University Of South Florida Nanoparticle targeted drug delivery to the lungs using extra-testicular sertoli cells
US8709400B2 (en) * 2009-07-27 2014-04-29 Washington University Inducement of organogenetic tolerance for pancreatic xenotransplant
EP2470228B1 (de) 2009-08-28 2017-10-04 Sernova Corporation Verfahren und vorrichtungen für zelltransplantation
MX2010013135A (es) 2010-11-30 2012-05-31 Val De Bio S De R L De C V Procedimiento y dispositivo mejorados para favorecer el trasplante de material biológico.
US10532128B2 (en) 2015-11-18 2020-01-14 Viera Bioscience, Inc. Implantable cellular therapy device for treatment of graft versus host disease and tolerance induction
WO2019079384A1 (en) 2017-10-17 2019-04-25 The Methodist Hospital System Delivery devices
US20220211770A1 (en) 2019-05-01 2022-07-07 Sernova Corporation Methods of treating diabetes using devices for cellular transplantation
BR112023025612A2 (pt) * 2021-06-30 2024-02-27 Polbionica Sp Z O O Meio para armazenar ilhotas pancreáticas isoladas, e, método de armazenamento de ilhotas pancreáticas isoladas

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158874A (en) * 1985-08-30 1992-10-27 The United States Of America As Represented By The Department Of Health And Human Services Determining metastic potential of tumor cells and isolating metastic tumor cells
US4829000A (en) * 1985-08-30 1989-05-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Reconstituted basement membrane complex with biological activity
US5053332A (en) * 1989-07-24 1991-10-01 Cook Richard B Agarose beads, preferably incorporating biological materials
US5304603A (en) * 1991-06-18 1994-04-19 The Population Council Leydig cell stimulator
DE4227066A1 (de) * 1992-08-16 1994-02-17 Bernhard Josef Dr Med Hering Langerhans'sche Inseln in reiner Form
US5474905A (en) * 1993-11-24 1995-12-12 Research Corporation Technologies Antibodies specific for streptococcus pneumoniae hemin/hemoglobin-binding antigens
US5849285A (en) * 1994-04-13 1998-12-15 Research Corporation Technologies, Inc. Autoimmune disease treatment with sertoli cells and in vitro co-culture of mammal cells with sertoli cells

Also Published As

Publication number Publication date
FI964033A0 (fi) 1996-10-08
CA2187803C (en) 1999-09-28
WO1995028167A1 (en) 1995-10-26
DE69525151T2 (de) 2002-08-14
US5843430A (en) 1998-12-01
FI964033L (fi) 1996-12-12
ES2169128T3 (es) 2002-07-01
DE69525151D1 (de) 2002-03-14
EP0755258A1 (de) 1997-01-29
FI20085733L (fi) 2008-07-18
NO320713B1 (no) 2006-01-23
FI120670B (fi) 2010-01-29
US5759534A (en) 1998-06-02
AU2289395A (en) 1995-11-10
NO964342D0 (no) 1996-10-11
DK0755258T3 (da) 2002-05-13
JPH09512015A (ja) 1997-12-02
FI120696B (fi) 2010-01-29
AU715177B2 (en) 2000-01-20
EP0755258B1 (de) 2002-01-23
US5725854A (en) 1998-03-10
NO964342L (no) 1996-12-13
CA2187803A1 (en) 1995-10-26

Similar Documents

Publication Publication Date Title
DE69525151D1 (de) Methoden zur krankheitsbehandlung unter verwendung von sertoli-zellen und allotransplantat oder xenotransplantat
DE69527521D1 (de) Behandlung von biologischen materialen vor der fixierung
MD1444B2 (ro) Metode de inducere a toleranţei celulelor T faţă de un transplant de organe sau ţesuturi
DE3779149D1 (de) Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit.
NO960711L (no) Neural regenerering ved anvendelse av humane ben-morfogneiske proteiner
DK0702563T3 (da) Sammensætninger og fremgangsmåder til behandling af cancer og hyperproliferative sygdomme
EE9700225A (et) Meetod diabetes mellituse raviks, kasutades KKF
DE69635924D1 (de) Isolierung und züchtung von schwannzellen
EA199700241A1 (ru) Новые, определенные по составу смеси ферментов для выделения клеток и лечения ран
DE60039160D1 (de) Verwendung von erbb-rezeptorliganden zur behandlung von diabetes
BR0213429A (pt) Métodos para regenerar a função do pâncreas em um indivìduo, para tratar o diabete em um paciente humano e para produzir célula pancreática funcional de animal, célula pancreática funcional de animal, uso da mesma, e, método para roduzir célula pancreática de animal em diferentes estágios de desenvolvimento
DE60037876D1 (de) Verfahren zur Herstellung von entwickelten und unentwickelten Pankreasendokrinezellen, Zellpräparat und Verwendung davon zur Behandlung von Diabetes
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
NO912621L (no) Fremgangsmaate for innfoering av dna i animalske celler.
ATE264112T1 (de) Verwendung von il-7 zur behandlung von autoimmunkrankheiten, insbesondere insulinabhängigem diabetes mellitus
TW200507875A (en) Remedy for diabetes
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
TR199802706T2 (xx) Bir bitki hastal���n�n iyile�tirilmesi i�in y�ntem.
WO2004030628A3 (en) Adult bone marrow derived stem cells
NO20012214L (no) Fremstilling av en biologisk faktor og frembringelse av et immunologisk fordelaktig miljö ved anvendelse av genetiskforandrede Sertoliceller
DE69433851D1 (de) Tiermodell zum testen von arzneistoffen zur behandlung von leukämie oder hiv
ATE275192T1 (de) Neue therapeutische verwendungen der heterologen superoxiddismutasen (hsd), sowie verfahren zur selektierung dieser hsd
DE69001240D1 (de) Methoden zur verwendung von 2-isopropyl-2-phenylaminovaleriansaeurenitrilen als immunosupressoren und vasodilatoren.
GEP19970991B (en) Method for Decay of Tumor Cells with Mammalia and Pharmacentical Composition for this Purpose
CY1107379T1 (el) Μια μεθοδος παραγωγης παρασκευασματων που αποτελουνται απο ωριμα και ανωριμα παγκρεατικα ενδοκρινη κυτταρα, το παρασκευασμα κυτταρων και η χρηση του στην θεραπεια του διαβητη mellitus

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification